The total return over the past 12 months is -7.67% vs. +16.94% for the S&P 500. So far it's up -48.13% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (7.67%) | (52.17%) | (48.68%) | N/A | N/A | N/A |
| Total Return CAGR | (7.67%) | (52.17%) | (48.68%) | N/A | N/A | N/A |
| Revenue CAGR | +106.21% | +52.15% | +20.37% | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Verrica Pharmaceuticals Inc. (VRCA)
| Year | Start price | End price | VRCA Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $8.31 | $4.31 | (48.13%) | +14.51% | (62.64%) |
| 2025 | $7.00 | $8.31 | +18.71% | +17.72% | +0.99% |
| 2024 | $73.20 | $7.00 | (90.44%) | +24.89% | (115.33%) |
| 2023 | $27.50 | $73.20 | +166.18% | +26.19% | +139.99% |
| 2022 | $91.60 | $27.50 | (69.98%) | (18.17%) | (51.81%) |
| 2021 | $115.10 | $91.60 | (20.42%) | +28.74% | (49.16%) |
| 2020 | $158.90 | $115.10 | (27.56%) | +18.37% | (45.93%) |
| 2019 | $81.50 | $158.90 | +94.97% | +31.22% | +63.75% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
